Proactive Investors - Novo Nordisk (CSE:NOVOb) unveiled a potential game changer during its Capital Markets Day with data on experimental obesity pill amycredtin potentially outperforming its blockbuster drug Wegovy.
An early-stage test conducted over 12 weeks showed patients taking the pill lost 13% of their weight.
Though trials are still in their early stages, Novo Nordisk hopes it can add another killer app to its portfolio of weight-loss drugs.
Chief executive Lars Fruergaard Jorgensen told CMD attendees that the company was expanding its focus from weight loss to cardiovascular disease treatments.
His comments come after trials conducted last August showed Wegovy reduced cardiovascular events by 20% in overweight or obese adults in the Select trial compared with a placebo.
The successes of Wegovy and Novo Nordisk (NYSE:NVO)’s other injection-based obesity drug Ozempic have turned the Danish pharma group into continental Europe’s most valuable company.
Luxury goods conglomerate LVMH (EPA:LVMH) was formerly Europe’s largest company.
Earlier this week, Novo Nordisk said diabetes patients were able to prevent the onset of chronic kidney disease in trials of Ozempic and Wegovy, which both belong to the semaglutide class of medications.
The Danish drug giant hailed the headline results from its FLOW trial which reduced kidney disease progression, major adverse cardiovascular events and death by 24% compared to a placebo.
Shares in the group reached a new all-time high today after rallying over 5% on the Copenhagen exchange to give the group a US$428 billion market capitalisation.